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Abstract
The gram-negative bacterium Yersinia pestis causes plague, a rapidly progressing and often fatal
disease. The formation of fibrin at sites of Y. pestis infection supports innate host defense against
plague, perhaps by providing a non-diffusible spatial cue that promotes the accumulation of
inflammatory cells expressing fibrin-binding integrins. This report demonstrates that fibrin is an
essential component of T cell-mediated defense against plague but can be dispensable for
antibody-mediated defense. Genetic or pharmacologic depletion of fibrin abrogated innate and T
cell-mediated defense in mice challenged intranasally with Y. pestis. The fibrin-deficient mice
displayed reduced survival, increased bacterial burden, and exacerbated hemorrhagic pathology.
They also showed fewer neutrophils within infected lung tissue and reduced neutrophil viability at
sites of liver infection. Depletion of neutrophils from wild type mice weakened T cell-mediated
defense against plague. The data suggest that T cells combat plague in conjunction with
neutrophils, which require help from fibrin in order to withstand Y. pestis encounters and
effectively clear bacteria.
Introduction
Yersinia pestis is the gram-negative facultative intracellular bacterium that causes plague
(1). Pandemics of plague have killed hundreds of millions of people during recorded history,
but rodents are the primary hosts for Y. pestis in nature. Plague is transmitted between
rodents by fleas, which regurgitate the Y. pestis bacteria into dermal tissue as they take a
blood meal (2, 3). The infected rodents develop bacteremia, facilitating the infection of new
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fleas, and then succumb to sepsis, presumably encouraging infected fleas to seek new hosts.
Humans are incidental hosts whose infections typically result from fleabites or the handling
of infected animals.
Naïve rodents succumb to plague after the inoculation of as few as 10 Y. pestis CFU. This
extreme virulence results primarily from the capacity of Y. pestis to overwhelm innate
immune defense mechanisms. A number of distinct virulence mechanisms have been
established. For example, a pCD1 plasmid-encoded type III secretion system (T3SS) injects
mammalian cells with proteins that inhibit phagocytosis, suppress oxidative burst, and
induce apoptosis (4). In addition to actively combating innate immunity with its T3SS, Y.
pestis also evades innate immunity by surrounding itself with an F1 protein that creates an
anti-phagocytic capsule (5) and by producing a tetra-acylated form of LPS that antagonizes
host recognition by TLR4 (6-8).
Infected humans commonly present with hugely swollen draining lymph nodes, called
buboes, which can progress to bacteremia, sepsis and/or pneumonia. Left untreated, all
forms of human plague have high mortality. The pneumonic form is particularly fulminant
and can be spread from person to person via infectious respiratory droplets (9-11). Today's
public health infrastructure, coupled with the availability of effective antibiotics, greatly
reduces the likelihood of a natural modern-day pandemic. Nevertheless, effective vaccines
are sought because Y. pestis is one of the world's most deadly human pathogens, remains
endemic in rodent populations around the world, and has been weaponized (12). A better
understanding of the basic mechanisms underlying Y. pestis pathogenesis and host defense
should facilitate the development of effective countermeasures.
Fibrin is best appreciated for its capacity to limit blood loss in response to vascular trauma.
Damage to the vasculature activates fibrin formation by exposing plasma to extravascular
cells that constitutively express tissue factor (TF)6, the primary activator of blood
coagulation pathways (13, 14). TF interacts with plasma-derived clotting factors to initiate
enzymatic cascades that generate thrombin, a protease that cleaves fibrinogen, prompting its
polymerization and deposition as insoluble fibrin. Excessive or inappropriate blood clotting
can produce thrombotic occlusions that impede blood flow, so the formation of fibrin and its
degradation (i.e. fibrinolysis) are tightly regulated processes. The primary mediator of
fibrinolysis is plasmin, a fibrin-degrading protease generated by partial proteolysis of an
inactive precursor, plasminogen (15).
Like many other bacterial pathogens, Y. pestis produces an enzyme that activates
fibrinolysis in mammalian hosts (16, 17). Specifically, the Y. pestis Pla protein promotes
fibrinolysis by activating host plasminogen while inactivating alpha-2-antiplasmin,
plasminogen activator inhibitor 1 (PAI-1) and thrombin activatable fibrinolysis inhibitor
(TAFI) (18-22). Deletion of Pla attenuates Y. pestis virulence in mouse models of bubonic
plague, where the plague-causing bacteria are inoculated subcutaneously or intradermally (2,
19, 23). In these bubonic models, Pla-deficient Y. pestis grow to high titer at the peripheral
injection site but typically fail to attain high titers in draining lymph nodes and distal organs
(2, 19, 23), suggesting that Pla facilitates the digestion of fibrin matrices at peripheral sites
of infection, thereby disrupting physical barriers that impede bacterial dissemination (24,
25). Consistent with that possibility, Pla-deficient strains regain high levels of virulence
when injected subcutaneously into fibrinogen-deficient mice, which lack the capacity to
produce fibrin matrices (26).
6Abbreviations: TF, tissue factor; PAI-1, plasminogen activator inhibitor 1; TAFI, thrombin activatable fibrinolysis inhibitor; FXI,
factor XI.
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In addition to facilitating dissemination from peripheral tissue, Pla, plasminogen and
fibrin(ogen) also impact the nature of inflammatory cell accumulations at sites of Y. pestis
infection. Inoculation of Pla-deficient Y. pestis promotes the formation of neutrophil-rich
lesions, whereas inoculation of wild type strains leads to the formation of lesions that
contain few inflammatory cells (2, 19, 26). These studies suggest that Pla-mediated
fibrinolysis may facilitate Y. pestis dissemination by reducing the accumulation and/or
activation of inflammatory cells with the capacity to destroy Y. pestis bacteria (26, 27).
Early studies suggested that this interplay between Pla and fibrin might be less important
during primary pneumonic plague (28). However, elegant genetic studies by Lathem and
colleagues demonstrated that Pla mutants fail to colonize lung tissue at high levels upon
intranasal inoculation into mice, even though both wild type and mutant strains ultimately
escape the lung and cause lethal sepsis (29). Nevertheless, functional roles for fibrin have
yet to be established in models of pulmonary Y. pestis infection. Moreover, all prior reports
describing roles for fibrin(ogen) during host defense against Y. pestis, and other infections,
have used naïve mice and focused exclusively on innate immune defense mechanisms. Roles
for fibrin during acquired immune defense against plague, or any other infectious disease,
have not been reported. The studies described here aimed to dissociate impacts of fibrin on
innate, antibody, and T cell-mediated defense using mouse models of septic pneumonic
plague. The findings demonstrate that fibrin can be essential for both innate and T cell-
mediated defense but dispensable for antibody-mediated defense. In these models, fibrin
does not appear to act solely as a spatial cue for the accumulation of inflammatory cells but,




All animal studies were conducted in accordance with Trudeau Institute Animal Care and
Use Committee guidelines. Experimental mice were bred in a specific-pathogen-free facility
at Trudeau Institute. Breeder stocks of C57BL/6 wild type mice, B cell-deficient μMT mice,
and PAI-1-deficient mice were obtained from The Jackson Laboratory (Bar Harbor, ME).
Breeder stocks of C57BL/6 fibrinogen-deficient mice (30), Factor XI (FXI)-deficient mice
(31), and TAFI-deficient mice (32) were supplied by Jay L. Degen, David Gailani and
Edward F. Plow, respectively. PAI-1/TAFI-deficient mice were generated at Trudeau
Institute (33). Nigel Mackman supplied breeder stock of C57BL/6 mice with very low levels
of TF activity (low-TF mice). These mice lack expression of mouse TF due to its
inactivation by gene targeting and instead express a human TF transgene, which imparts
low-level TF activity (mTF-/-hTF+) (34). Low-TF mice were compared with littermates
expressing human TF that were heterozygous for mouse TF (het-TF; mTF+/-hTF+).
Experimental mice were matched for age and sex, and infected or vaccinated between 6 and
10 weeks of age. Where indicated, wild type mice were anticoagulated pharmacologically
by supplementing drinking water with 2 mg/liter coumadin [3-(α-acetonylbenzyl)-4-
hydroxycoumarin; Sigma-Aldrich] beginning 3 days prior to infection with replenishment
every 48 hours; this anticoagulant regimen reduces fibrin deposition in mice during infection
(35).
Bacterial infections
Y. pestis strain KIM D27 (pgm-negative, pCD1+, pPCP+, pMT+) and KIM D28 (pgm-
negative, pCD1-, pPCP+, pMT+) were provided by Dr. Robert Brubaker (Michigan State
University, East Lansing, MI). Attenuated strain D27-pLpxL was generated as described
previously (36) by transforming strain KIM D27 with plasmid pLpxL, which was provided
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by Drs. Egil Lien and Jon Goguen (University of Massachusetts Medical School, Worcester,
MA). For infections, strain D27 was grown overnight at 26°C in Bacto heart infusion broth
(BHI; Difco Laboratories, Detroit, MI) supplemented with 2.5 mM CaCl2. Cultures were
then diluted to an optical density of 0.1 at 620nm, re-grown in the same media for 3-4 hours
at 26°C, quantified by measuring the optical density, and resuspended in saline at the desired
concentration. Infections were performed by applying 30 ul to the nares of mice that were
lightly anesthetized with isoflurane. The number of bacteria in the inoculating dose was
confirmed by plating on BHI agar. The median lethal dose for strain KIM D27, as calculated
also by the method of Reed and Muench (37), is approximately 1×104 CFU when grown and
administered as described above. Strain D27-pLpxL was grown and administered as
described for strain KIM D27, except the broth was supplemented with 100 ug/ml ampicillin
(36). The median lethal dose for strain D27-pLpxL is greater than 1×107 CFU when
administered via the intranasal route (36).
Measurements of survival and bacterial burden
Mice were monitored at least once daily after initiating infection. Unresponsive or
recumbent animals were considered moribund and euthanized. To measure bacterial burden,
tissues were collected from mice that were euthanized by carbon dioxide narcosis. The
number of viable bacteria in lung, spleen, and liver were measured by homogenizing tissues
in saline, plating serial dilutions on BHI agar, and counting CFU after 48 hours growth at
26°C.
Immunotherapy
Hybridoma clones F1-04-A-G1 and 7.3 producing F1- and LcrV-specific mAb, respectively,
were described previously (38-41). The mAb produced by these hybridomas were purified
using protein G agarose. They contained less than 2.2 units per mg endotoxin as measured
by Limulus Amebocyte Lysate assay. For passive immunotherapy, mice were treated with
the indicated doses of mAb diluted in phosphate-buffered saline and administered
intraperitoneally. Control mice received equivalent doses of isotype-matched non-protective
LcrV-specific mAb (mouse IgG1; clone 26-2).
Adoptive T cell transfers
Cells for adoptive transfer were harvested from μMT mice that had been immunized with
D27-pLpxL (2×106 CFU) and rested for 60 days (36). Cells were isolated from spleens,
restimulated in vitro in bulk culture with mitomycin c-treated naïve splenocytes as antigen
presenting cells and heat-killed Y. pestis strain KIM D27 grown at 37°C as antigen (42).
Two days after initiation of culture, an equal volume of medium containing 40 units/ml
recombinant human interleukin-2 was added. The cultures were replenished with
interleukin-2-containing medium every other day. After two weeks of culture, cells were
harvested, counted and injected intravenously into recipient mice (5×106 viable cells/
mouse), which were challenged with Y. pestis the following day.
Immunizations with YopE and ovalbumin peptides
Peptide YopE69-77 (H2N-SVIGFIQRM-OH) and control ovalbumin peptide OVA257-264
(H2N-SIINFEKL-OH) were synthesized and purified (>95%) by New England Peptide
(Gardner, MA). Mice were lightly anesthetized by isoflurane and immunized intranasally
with a 15 ul saline solution containing 10 ug peptide and 1 ug cholera toxin (List Biological
Laboratory, Campbell, CA). Mice were immunized on days 0, 7, and 21, and challenged
with Y. pestis strain D27 on day 37. When indicated, neutrophils were depleted in vivo by
intraperitoneal injection of 0.2 mg of Ly6G-specific mAb (clone 1A8; BioXcell) on days 36,
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38, 40 and 42; control mice received injections of isotype-matched rat IgG2a mAb
(BioXcell).
Flow cytometry
Preparation of lung cells (43) and enumeration of YopE-specific CD8 T cells by
KbYopE69-77 tetramer staining (42) was described previously. In brief, cells isolated from
lung tissue digested with collagenase and DNAse were incubated with Fc Block (clone
2.4G2) for 15 minutes at 4°C, washed, and incubated with tetramer for 1 hour at room
temperature. The allophycocyanin-conjugated KbYopE69-77 tetramer was supplied by the
NIH Tetramer Facility. After washing again, cells were stained with anti-CD8-peridinin
chlorophyll protein (clone 53-6.7) for 30 minutes at 4°C. For enumeration of CD4 cells, NK
cells and neutrophils, lung samples were stained on ice with anti-CD4 peridinin chlorophyll
protein (clone RM4-5) and anti-NK1.1-phycoerythrin (clone PK136), anti-CD11b-
allophycocyanin (clone M1/70) and anti-Ly6G-fluorescein isothiocyanate (clone 1A8). Data
were gated for forward scatter/side scatter and collected on a Beckton Dickinson
FACSCanto II and analyzed using FlowJo software.
Histology and immunofluorescent staining
Tissues were fixed in 10% neutral buffered formalin, embedded in paraffin, sectioned, and
stained with hematoxylin and eosin. Representative photomicrographs are presented at a
magnification of 400x. The number of focal lesions per tissue section were quantified and
assigned scores of: 1 when characterized by mixed inflammatory cells with little to no
evidence of tissue damage, 2 when marked by contiguous areas of anoxic hepatocytes and/or
mild hepatocellular necrosis with little to no evidence of bleeding, 3 when consisting of
broad areas of hepatocellular necrosis interspersed with notable evidence of bleeding
comprising 5-25% of the total lesion area, and 4 when presenting as broad areas of
contiguous hemorrhage comprising greater than 25% of the total lesion area. For
immunofluorescent staining, 7um frozen sections of OCT-embedded liver tissues were air
dried for 10 minutes and fixed in a mixture of acetone and ethanol (75:25) for 10 minutes at
room temperature. Tissues were rinsed with PBS, blocked with 5% normal mouse serum for
30 minutes, and then incubated with primary antibodies diluted in PBS with 5% normal
mouse serum for 1 hour at room temperature. The anti-F1 antibody was conjugated to
Dylight 488 using the Dylight 488 microscale antibody labeling kit from (Thermo Fisher)
and used at a 1:200 dilution. Ly6G-phycoerythrin (BD Pharmingen) and F4/80-AF647 (AbD
Serotech) were used at 1:200 and 1:75 dilutions, respectively. After rinsing, the tissues were
counterstained with Hoechst nuclear dye. Slides were imaged using a Leica SP5 confocal
microscope with 405, 488, 543, and 633 laser lines. Emission spectra were collected using
the appropriate bandwidth settings for each fluorophore.
Measurements of hepatic fibrin deposition
Fibrin levels within tissue samples were quantified essentially as described previously (44)
and scored positive when above the limit of detection (10 ng/mg tissue). In brief, insoluble
fibrin was extracted from homogenized tissue and quantified by Western blot using
biotinylated fibrin-specific mAb 350 (American Diagnostica) followed by rabbit anti-biotin
(Bethyl Labs), anti-rabbit horseradish peroxidase polymer (DakoCytomation), and
chemiluminescent detection (Bio-Rad). Standard curves were generated by treating purified
mouse fibrinogen (Sigma-Aldrich) with human thrombin (Enzyme Research Laboratories).
Real-time PCR
Tissue levels of mRNA encoding TNFα, IFNγ, IL-6, IL-10, CXCL-1, lipocalin-2, TF, FXI,
PAI-1, and TAFI were measured by real-time PCR (PerkinElmer), normalized to levels of
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mRNA encoding GAPDH, and expressed as fold change relative to levels in uninfected wild
type mice (45).
Statistics
Statistical analyses were performed using the program Prism 5.0 (GraphPad Software, Inc.).
Survival data were analyzed by log rank tests. All other data were analyzed by Mann-
Whitney tests, unless indicated otherwise in figure legends. When CFU or fibrin samples fell
below the detection limit of our assays they were assigned log10 values of 1.0 or 0.5,
respectively.
Results
Fibrinogen contributes to innate defense against Y. pestis
Y. pestis strain KIM D27 possesses a functional T3SS but is attenuated when inoculated
subcutaneously into mice owing to the deletion of a 102-kb chromosomal region that
encodes a number of proteins, including some associated with iron utilization (1).
Nevertheless, KIM D27 retains much of its virulence when administered intranasally (43).
Figure 1A demonstrates that wild type C57BL/6 mice and RAG-deficient C57BL/6 mice
succumbed with similar kinetics after intranasal challenge with 2×105 CFU KIM D27,
which is approximately 20 times the median lethal dose for wild type mice (43). Since
RAG-deficient mice lack B and T cells, the mediators of adaptive immunity, these data
indicate that adaptive immunity has little impact on the time to morbidity in naïve mice
challenged with KIM D27. Analyses of bacterial burden in lung and liver tissue at day 4
after challenge likewise failed to reveal a significant role for adaptive immunity during host
defense against lethal challenge with KIM D27 in naïve mice (not shown).
Fibrinogen-deficient mice succumbed more rapidly to plague than littermate control
fibrinogen-heterozygous mice when challenged intranasally with KIM D27 (Figure 1B). The
bacterial burden measured at day 4 after challenge revealed a modest but significant increase
in numbers of CFU in the lung and liver tissues of fibrinogen-deficient mice, as compared
with controls (Figure 1C). Thus, even though Y. pestis rapidly overwhelms innate host
defense in wild type mice (Figure 1A), fibrinogen nevertheless plays a significant protective
role in that setting.
To formally demonstrate that fibrinogen contributes to innate defense, fibrinogen-deficient
mice and RAG-deficient mice were intercrossed to generate RAG-deficient mice that were
fibrinogen-deficient or fibrinogen-heterozygous. When these RAG-deficient mice were
challenged with KIM D27, the modest but significant impacts of fibrinogen-deficiency on
mortality and bacterial burden were still evident (Figures 1D and 1E). These data provide
additional evidence of fibrinogen's role in innate defense against Y. pestis.
Roles for fibrin during innate defense against plague were more dramatic when fibrinogen-
deficient mice were challenged with D27-pLpxL, a highly attenuated derivative of KIM
D27. Intranasally administered D27-pLpxL is avirulent in wild type mice owing to its
engineered, constitutive expression of hexa-acylated forms of LPS, which potently stimulate
innate immunity by triggering TLR4 (6). All wild type and most RAG-deficient mice
survived intranasal challenge with 2×106 CFU D27-pLpxL (Figure 1F), confirming a
prominent role for innate immunity in defense against attenuated strains that constitutively
express hexa-acylated LPS (6). In contrast, nearly all fibrinogen-deficient mice succumbed
to challenge with D27-pLpxL (Figure 1G). Notably, some fibrinogen-heterozygous mice,
which possess approximately 70% the level of fibrinogen as wild type mice (30), also
succumbed to D27-pLpxL challenge (Figure 1G). The day 4 bacterial burden in lung and
liver were significantly elevated in fibrinogen-deficient mice challenged with D27-pLpxL,
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as compared with fibrinogen-heterozygous mice (Figure 1H). In fact, the burden of D27-
pLpxL achieved levels approaching that of KIM D27 in fibrinogen-deficient mice (compare
Figures 1C and 1H). RAG/fibrinogen-deficient mice also displayed high susceptibility to
D27-pLpxL challenge, as measured by survival and bacterial burden (Figures 1I and 1J),
thus formally demonstrating that fibrinogen contributes substantially to the innate defense
mechanisms that mediate the attenuation of Y. pestis strain D27-pLpxL.
The attenuation of D27-pLpxL is thought to result from its capacity to evoke a strong
immune response (36). The attenuation of KIM D28, another derivative of KIM D27, results
from its inability to resist innate defense due to the loss of the pCD1 plasmid-encoded T3SS.
In contrast to fibrinogen-deficient mice challenged with D27-pLpxL (Figure 1G),
fibrinogen-deficient mice readily survived intranasal challenge with KIM D28 (2×106 CFU;
not shown). These data indicate that, depending upon the means of attenuation for a given
Y. pestis strain, fibrinogen either can be critical or dispensable for innate immune defense.
Fibrinogen can be dispensable for antibody-mediated defense against Y. pestis
The fibrinogen-deficient mice that survived challenge with KIM D28 subsequently
withstood intranasal challenge with 2×105 CFU KIM D27 (not shown). This observation
suggested that fibrinogen can be dispensable for defense against KIM D27 in mice that have
been immunized such that they possess Y. pestis-specific acquired immunity.
To definitively assess requirements for fibrinogen during acquired immunity, mice were
challenged with Y. pestis and then supplied with antibody-mediated defense. Specifically,
mice were infected intranasally with 2×105 CFU KIM D27 and then treated one day later
with 10 ug LcrV-specific mAb 7.3. LcrV is a critical component of the T3SS (4) and prior
studies established that therapeutic administration of 10 ug mAb 7.3 protects wild type mice
from intranasal challenge with KIM D27 (40). This anti-LcrV immunotherapy protocol fully
protected fibrinogen-deficient mice (Figure 2A). Analyses of day 4 bacterial burdens in lung
and liver tissues likewise failed to discern differences between control and fibrinogen-
deficient mice treated with 10 ug LcrV-specific mAb 7.3 (Figures 2B and 2C). Analogous
studies using a mAb specific for F1, the Y. pestis capsular protein, likewise demonstrated
that antibodies could protect fibrinogen-deficient mice against lethal intranasal challenge
with KIM D27 (Figure 2D). Together, these data indicate that fibrinogen is not required for
antibody-mediated defense against virulent Y. pestis.
Prior studies revealed distinct mechanisms of antibody-mediated protection depending upon
the dose of immunotherapy (40). When fibrinogen-deficient mice were infected intranasally
with KIM D27 and then treated therapeutically with a ten-fold lower, suboptimal dose of
LcrV-specific mAb (i.e. 1 ug), most wild type and fibrinogen-heterozygous mice survived,
whereas significantly fewer fibrinogen-deficient mice withstood the challenge (Figure 2E).
Analyses of day 4 bacterial burdens revealed significantly increased bacterial CFU in lung
and liver tissue from fibrinogen-deficient mice (Figures 2F and 2G). Similar results were
observed when mice received a ten-fold lower dose of F1-specific mAb (Figure 2H). Thus,
fibrinogen is dispensable for immunotherapeutic protection against KIM D27 when optimal
doses of protective mAb are used (Figures 2A-2D) but plays a significant role during
suboptimal immunotherapy (Figures 2E-2H).
Fibrinogen is essential for T cell-mediated defense against Y. pestis
The cytokines TNFα and IFNγ contribute to protection against plague in the suboptimal
immunotherapy model, suggesting a role for type 1 T cells (40, 41). To assess requirements
for fibrinogen during T cell-mediated defense against Y. pestis, mice were supplied with Y.
pestis-specific T cells and then challenged intranasally with 2×105 CFU KIM D27. In a first
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set of experiments, cellular immunity was supplied by intravenously injecting a polyclonal
line of T cells derived from splenocytes of D27-pLpxL-immunized B cell-deficient μMT
mice that had been expanded in vitro by culture with heat-killed KIM D27 (43). One day
following the transfer of 5×106 T cells, fibrinogen-deficient and control mice were
challenged intranasally with KIM D27. All wild type mice that received culture medium
alone succumbed to Y. pestis challenge, whereas all wild type mice that received T cells
survived (Figure 3A). Most fibrinogen-heterozygous mice that received T cells also
survived, whereas the fibrinogen-deficient mice all succumbed (Figure 3A). Analyses of day
4 bacterial burdens confirmed that T cell transfer significantly reduced the number of Y.
pestis CFU in lung and liver tissue of wild type mice (Figures 3B and 3C). The bacterial
burden was significantly higher in fibrinogen-deficient mice, as compared with littermate
controls, and resembled that of control wild type mice that did not receive T cells (Figures
3B and 3C).
The polyclonal T cell lines contained, on average, 38% CD4- and 62% CD8-positive T cells.
A large fraction of Y. pestis-specific CD8 T cells in C57BL/6 mice recognize YopE69-77, a
peptide fragment of the Y. pestis T3SS YopE protein (42). To specifically assess roles for
fibrinogen during CD8 T cell-mediated defense against virulent Y. pestis, fibrinogen-
deficient mice were immunized with YopE69-77 and then challenged intranasally with KIM
D27. Consistent with prior studies (42), YopE69-77-immunized wild type mice showed
significantly improved survival as compared with wild type mice immunized with a control
ovalbumin peptide (Figure 3D). YopE69-77-immunized fibrinogen-deficient mice displayed
significantly reduced survival as compared with fibrinogen-heterozygous controls (Figure
3D). Analyses of day 4 bacterial burdens revealed that YopE69-77 immunization reduced
bacterial CFU to a significantly greater extent in the lung and liver tissue of fibrinogen-
heterozygous mice, as compared with fibrinogen-deficient mice (Figures 3E and 3F).
Neutrophils contribute to T cell-mediated defense against Y. pestis
The failure of YopE69-77 immunization to protect fibrinogen-deficient mice from plague
(Figure 3D-3F) could have resulted from a failure to prime and expand T cells. To assess
this possibility, flow cytometric studies were performed using a KbYopE69-77 tetramer that
specifically binds YopE69-77-specific CD8 T cells (42). In comparison with unimmunized
mice, the number of pulmonary YopE69-77-specific CD8 T cells increased approximately
100-fold in YopE69-77-immunized mice (Figure 4A). The magnitude of this priming was
similar in fibrinogen-deficient and littermate control fibrinogen-heterozygous mice. Four
days after challenge with KIM D27, fibrinogen-deficient and heterozygous mice still
harbored similar numbers of pulmonary YopE69-77-specific CD8 T cells (Figure 4A). The
fibrinogen-deficient and heterozygous mice also harbored similar numbers of total
pulmonary CD8 cells, CD4 cells, and NK cells (not shown). Interestingly, the number of
Ly6G-expressing neutrophils was similar in the unchallenged mice but decreased
significantly in the fibrinogen-deficient mice, as compared with control heterozygous mice,
at day 4 after challenge with KIM D27 (Figure 4B).
To assess whether a decrease in neutrophil numbers compromises T cell-mediated defense
against plague, wild type mice were immunized with YopE69-77 and then neutrophils were
depleted at the time of Y. pestis challenge. Specifically, mice were treated with Ly6G-
specific mAb or isotype-matched control mAb on days -1, 1, 3, and 5 relative to challenge
with KIM D27. YopE69-77-immunized mice treated with Ly6G-specific mAb displayed
significantly reduced survival in comparison with YopE69-77-immunized mice treated with
control mAb (Figure 4C).
Luo et al. Page 8













Fibrinogen restrains hemorrhagic pathology during innate and T cell-mediated defense
against Y. pestis
Fibrin(ogen) can function protectively during infection by restraining bacterial growth/
dissemination and/or by suppressing hemorrhagic pathology (27, 33, 35, 44, 46-50). The
data presented in Figures 1-3 indicate that fibrinogen restrains the bacterial burden during Y.
pestis infection. To investigate whether fibrin(ogen) also suppresses hemorrhage in this
setting, tissues were subjected to histological analysis (Figure 5). On day 4 after challenge
with KIM D27, fibrinogen-heterozygous mice displayed evidence of hepatic necrosis with
lesions showing many pyknotic nuclei (Figures 5A and 5M). Fibrinogen-deficient mice
displayed similar pathology but fewer lesions contained identifiable nuclei and some lesions
showed areas of hemorrhage (Figures 5D and 5M). Infection with highly attenuated D27-
pLpxL induced a robust influx of inflammatory cells in both fibrinogen-heterozygous and
fibrinogen-deficient mice, but there was a greater propensity for hemorrhage in the
fibrinogen-deficient mice (Figures 5E and 5M). Likewise, there was a greater level of
hemorrhagic pathology in YopE-immunized fibrinogen-deficient mice challenged with KIM
D27, as compared with littermate controls (Figures 5F and 5M). Quantitative scoring
revealed that a significantly greater percentage of the lesions in the fibrinogen-deficient
mice showed evidence of hemorrhage (Figure 5N). Together, these observations indicate
that innate and T cell-mediated defense against Y. pestis is associated with hemorrhagic
pathology in fibrinogen-deficient mice.
Fibrinogen supports phagocyte viability during innate and T cell-mediated defense against
Y. pestis
To investigate the nature of the cellular response during innate and T cell-mediated defense
against Y. pestis, samples of hepatic tissue were subjected to immunofluorescent staining.
Many of the infiltrating cells observed in the naïve fibrinogen-heterozygous mice infected
with D27-pLpxL (Figure 5H) and in the YopE-immunized fibrinogen-heterozygous mice
infected with KIM D27 (Figure 5I) stained specifically with mAb that recognize
macrophages (F4/80; blue color) or neutrophils (anti-Ly6G; red color). The leukocyte
staining in these samples co-localized with dense clusters of nuclei, as revealed by co-
staining with the DNA intercalating Hoescht dye (white color). In striking contrast, the
lesions observed in all the fibrinogen-deficient mice (Figures 5J, 5K, 5L), as well as the
naïve fibrinogen-heterozygous mice infected with KIM D27 (Figure 5G), generally lacked
evidence of Hoescht-staining nuclei even though they still stained specifically with
macrophage and neutrophil markers.
Figures 5G-5L also show staining of Y. pestis bacteria using a mAb that recognizes the
capsular F1 protein (green color). Specifically, anti-F1 staining readily detected bacteria
within many of the lesions of naïve mice infected with KIM D27 (Figures 5G and 5J).
Bacteria were rarely observed in the lightly colonized naïve fibrinogen-heterozygous mice
infected with D27-pLpxL (Figure 5H) and YopE-immunized fibrinogen-heterozygous mice
infected with KIM D27 (Figure 5I) but, consistent with the CFU data (Figures 1H and 3F),
bacteria were often visualized in the lesions of the corresponding fibrinogen-deficient mice
(Figures 5K and 5L). Altogether, the data suggest that phagocytes were recruited to sites of
Y. pestis infection in fibrinogen-deficient mice but failed to survive their encounters with Y.
pestis bacteria.
Unimpaired inflammatory responses in fibrinogen-deficient mice infected with Y. pestis
The increased bacterial burden in liver tissue collected from fibrinogen-deficient mice
infected with Y. pestis could have resulted from impaired induction of a hepatic immune
response. However, real-time PCR measurements failed to discern any impairment in the
upregulation of mediators of inflammation and immunity (Figure 6). Rather, the fibrinogen-
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deficient and fibrinogen-heterozygous mice showed similar inductions of the cytokines
TNFα and IFNγ, the neutrophil chemoattractant CXCL1, and the antibacterial peptide
lipocalin-2. Levels of IL-6 and IL-10 mRNA also did not differ significantly between
fibrinogen-deficient and fibrinogen-heterozygous mice (not shown). These data are
consistent with prior studies demonstrating unimpaired induction of hepatic inflammatory
proteins in fibrinogen-deficient mice infected with T. gondii, L. monocytogenes, and Y.
enterocolitica (33, 35, 44).
Fibrin contributes to both innate and T cell-mediated defense against Y. pestis
The data presented thus far indicate a role for fibrinogen during innate and T cell-mediated
defense against plague. Fibrinogen is a circulating plasma protein that polymerizes and
deposits as insoluble fibrin upon its partial proteolysis by thrombin. Accordingly, a series of
studies were next undertaken to assess whether fibrin itself contributes to defense against
plague. Kinetic analyses in wild type mice revealed that intranasal inoculation of either
strain KIM D27 or strain D27-pLpxL resulted in similar levels of hepatic CFU on day 2 post
infection (Figure 7A), at which time quantitative immunoblotting of liver tissue first
revealed detectable levels of hepatic fibrin (Figure 7B). By day 4, liver tissue from mice
infected with KIM D27 contained significantly higher bacterial loads (Figure 7A) and fibrin
(Figure 7B), as compared with mice infected with D27-pLpxL. Likewise, by day 4 the
expression of genes whose products might contribute to fibrin formation had increased to a
significantly greater extent in mice infected with KIM D27 as compared with D27-pLpxL
(Figures 7C-F). While levels of mRNA encoding the procoagulant TF did not change
significantly during the course of either KIM D27 or D27-pLpxL infection (Figure 7C),
levels of the procoagulant FXI and the anti-fibrinolytic TAFI increased modestly and
achieved significantly higher levels in mice infected with KIM D27 as compared with D27-
pLpxL (Figures 7D and 7E). Levels of another anti-fibrinolytic, PAI-1, increased markedly
in mice infected with either KIM D27 or D27-pLpxL, but achieved significantly higher
levels in the KIM D27-infected mice (Figure 7F).
To assess functional roles for fibrin, studies were performed with mice possessing reduced
capacities to generate fibrin. First, mice with genetic impairments in coagulation pathways
leading to the production of thrombin were infected with Y. pestis. One set of mice was
deficient for expression of TF, the key initiator of thrombin-generating coagulation
pathways (13, 14). A second set of mice was deficient for expression of FXI, a key
component of the intrinsic coagulation pathway, which is not critical for thrombin
production but amplifies and sustains thrombin levels in certain settings (51-54). As shown
in Figure 8A, all FXI deficient mice survived challenge with D27-pLpxL, whereas mice
engineered to express very low levels of TF displayed significantly reduced survival as
compared with littermate control mice. YopE-immunized mice expressing very low levels of
TF also displayed significantly decreased protection as compared with littermate control
mice (Figure 8B). These observations suggest that TF-dependent production of thrombin,
which leads to the formation of fibrin, contributes to innate and T cell-mediated defense
against Y. pestis.
To confirm a role for thrombin, wild type mice were treated with coumadin, a
pharmacologic anticoagulant that reduces production of thrombin. Treatment with coumadin
significantly decreased survival of wild type mice infected with attenuated D27-pLpxL
(Figure 8C). Likewise, YopE-immunized wild type mice showed significantly decreased
protection when treated with coumadin at the time of challenge with KIM D27 (Figure 8D).
Given that coumadin reduces thrombin-mediated fibrin formation without impacting
fibrinogen levels, these findings suggest essential roles for fibrin during innate and T cell-
mediated defense against Y. pestis.
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Mice deficient in fibrin due to increased fibrinolysis, rather than decreased coagulation,
were used to further assess roles for fibrin in innate and T cell-mediated defense against
plague. PAI-1 and TAFI are two important regulators of fibrinolysis (15). PAI-1 suppresses
the activation of plasmin, the primary mediator of fibrinolysis (55), whereas TAFI cleaves
lysine residues from fibrin, thereby decreasing fibrinolysis by removing binding sites for
plasmin (56, 57). Prior studies established that genetic depletion of both PAI-1 and TAFI
decreases fibrin levels more than depletion of either one alone (33, 58). Control mice largely
survived infection with D27-pLpxL, whereas significantly fewer PAI-1/TAFI-deficient mice
survived (Figure 8E). Likewise, YopE-immunized PAI-1/TAFI-deficient mice showed
significantly reduced survival after challenge with KIM D27 (Figure 8F).
Discussion
Rodents are the primary natural reservoir for Y. pestis persistence (59, 60). Thus, mouse
models of plague provide the opportunity to study defense against a septic bacterial
pathogen in its natural host. This report investigated roles for fibrin(ogen) during innate and
adaptive immune defense against septic pneumonic plague resulting from the intranasal
inoculation of mice with Y. pestis. The studies reveal dramatic impairments in both innate
and T cell-mediated defense in (i) mice lacking fibrinogen, (ii) mice with very low levels of
TF procoagulant activity, (iii) mice with elevated levels of fibrinolytic activity, and (iv) mice
treated with the pharmaceutical anticoagulant coumadin (Figures 1, 3, and 8). The similar
impairments displayed by the mice used in this study strongly suggest that fibrin is an
important contributor to both innate and T cell-mediated defense in mouse models of
pneumonic plague.
A prior study by Lathem and colleagues indirectly suggested functional roles for fibrin
during innate defense in mice inoculated intranasally with Y. pestis (29). Our findings
support that possibility by directly demonstrating increased Y. pestis CFU within lung tissue
of mice lacking the capacity to produce fibrin (Figures 1-3). Multiple forms of fibrin-
mediated immunity have been proposed. None are mutually exclusive and their relative
importance may be context dependent. Fibrin-mediated “hemostatic immunity” appears to
play critical roles during Listeria and Toxoplasma infections. Challenging fibrin-deficient
mice with low doses of these pathogens causes hepatic bleeding, severe anemia, and
increased mortality (35, 44). The time at which fibrin-deficient mice succumb to Listeria and
Toxoplasma infections coincides with the time of peak anemia in wild type mice, suggesting
that fibrin prevents infection-induced hemorrhage in these models (35, 44). Blood-tinged
sputum is a diagnostic symptom of fulminant pneumonic plague in humans (9, 10),
suggesting a failure of hemostatic responses in that setting. Although, Y. pestis infection did
not cause significant anemia in the models of septic pneumonic plague described in this
report (data not shown), both innate and T cell-mediated defense against plague clearly
benefit from some degree of hemostatic immunity since the hepatic tissue of Y. pestis-
infected fibrinogen-deficient mice, but not littermate controls, was characterized by lesions
full of red blood cells (Figure 5).
Proteolytic fragments of fibrinogen may also contribute to fibrin-mediated defense against
plague. When it is cleaved by thrombin to create fibrin, fibrinogen releases a set of peptides
that are chemoattractant for monocytes, macrophages and neutrophils (61). However, these
fibrinopeptides seem unlikely to play major roles during fibrin-mediated defense against
plague since PAI-1/TAFI-deficient mice should produce wild type levels of fibrinopeptides
yet they appear phenotypically similar to fibrinogen-deficient mice during innate and T cell-
mediated defense against plague (Figure 8). Fibrin degradation products (FDPs) that result
from fibrinolysis also can regulate leukocyte functions (61). FDP levels should be normal or
elevated in PAI-1/TAFI-deficient mice, reduced in lowTF mice, and absent in fibrinogen-
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deficient mice. Given that all those mice display similar phenotypes during innate and T
cell-mediated immune defense against plague (Figure 8), FDPs seem unlikely to play a
major role in the models of fibrin-mediated immunity described herein.
Fibrin could contribute to innate and T cell-mediated immune defense against plague by
physically trapping Y. pestis bacteria, thereby limiting their growth and dissemination (24,
25). Trapping has long been considered a logical means of fibrin-mediated innate defense
against bacteria, and there is evidence for this mechanism during E. coli infections (46-48).
Physical restraint of Y. pestis bacteria by fibrin is one possible explanation for the decreased
dissemination of Pla-deficient strains from peripheral sites of infection (2, 19, 23). However,
Lathem and colleagues provided evidence that Pla is less important for Y. pestis
dissemination from lung tissue (29).
While the data presented here do not rule out a role for trapping, the liver histology provides
direct evidence that successful innate and T cell-mediated defense against plague
corresponds with fibrinogen-dependent accumulation of cellular infiltrates at sites of Y.
pestis dissemination (Figure 5). Fibrinogen is a ligand for a number of cell surface receptors
that facilitate leukocyte adhesion and activation, including CD11b/CD18, CD11c/CD18,
CD44, and TLR4 (27, 62-75). Since most phagocytes express the fibrin(ogen)-binding
integrins CD11b/CD18 and/or CD11c/CD18, it is easily conceivable that fibrin acts as an
inducible matrix supporting the accumulation of phagocytes at sites of infection. In addition
to providing an adhesive substrate, ligation of fibrin by fibrin(ogen)-binding receptors can
also activate phagocyte functions, including the secretion of chemokines that recruit
additional leukocytes (67-71, 73, 74, 76). In this manner, extravascular fibrin(ogen) can be
viewed as a danger-associated molecular pattern triggering leukocyte migration,
accumulation, and activation (71, 74). A particularly elegant in vivo demonstration of the
phagocyte-activating capacity of fibrin(ogen) was provided by Flick and colleagues who
engineered mice to only express fibrinogen molecules that lack a key binding site for CD11b
and CD11c integrins (27, 71). These mice displayed elevated bacterial burden in a model of
acute peritonitis and their peritoneal neutrophils appeared unable to kill phagocytosed S.
aureus bacteria (27, 71). A failure to control bacterial replication is likewise observed in
fibrinogen-deficient mice infected with S. aureus, group A Streptococcus, L. monocytogenes
and Y. enterocolitica (33, 35, 49, 50). Although a specific role for the CD11b/c-binding site
on fibrinogen has yet to be demonstrated in all these settings, it seems likely that fibrin
formation at sites of bacterial infection supports innate host defense by providing a non-
diffusible cue for the accumulation and activation of inflammatory cells that express fibrin-
binding integrins (26).
The studies reported here suggest that fibrin also affects leukocyte survival at sites of Y.
pestis infection. Fibrinogen can suppress neutrophil apoptosis in vitro (69, 77), likely via
interactions with CD11b/CD18 (78, 79). Fibrinogen-deficient mice implanted with
inflammatory microspheres develop suppurative lesions, whereas wild type mice develop
cellular infiltrates containing viable neutrophils (77). In naïve fibrin(ogen)-sufficient mice
infected with Y. pestis, the hepatic lesions that form contain pyknotic nuclei (Figure 5A) and
the presence of residual leukocyte membranes within these lesions suggests that Y. pestis
infection leads to the death of recruited leukocytes (Figure 5G). In the presence of effective
innate or T cell-mediated immunity, the hepatic tissue of fibrin(ogen)-sufficient mice
contains clusters of viable neutrophils and macrophages (Figures 5B, 5C, 5H, 5I), whereas
fibrinogen-deficient mice develop lesions characterized by residual leukocyte membranes
(Figures 5K, 5L). These findings extend the conclusions of Degen et al (26) by suggesting
that fibrin formation at sites of Y. pestis infection provides a non-diffusible cue for the
accumulation, activation, and enhanced survival of inflammatory cells.
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While prior studies have demonstrated that fibrin(ogen) contributes to innate defense against
bacterial infection, this is the first study to demonstrate that fibrin can be essential for T cell-
mediated defense. To our knowledge, there are no prior reports of defective T cell responses
in fibrin(ogen)-deficient mice. To the contrary, T cell-mediated control of pathogen burden
appears unimpeded in fibrin(ogen)-deficient mice challenged with T. gondii (44) or M.
tuberculosis (77), and here we showed unimpeded expansion of CD8 T cells in response to
vaccination with YopE69-77, an antigenic Y. pestis peptide (Figure 5A). Nevertheless, those
YopE-immunized mice displayed a significantly impaired capacity to restrain Y. pestis
growth and prevent plague (Figure 3 and 4A).
The failure of T cell-mediated defense in fibrin(ogen)-deficient mice infected with Y. pestis
appears to reflect a failure of neutrophils to survive encounters with bacteria in the absence
of fibrin(ogen)-dependent signals. The T cells primed in this Y. pestis model produce TNFα
and IFNγ (42). These cytokines can stimulate neutrophils (80-82), which can reduce Y.
pestis growth in vivo and in vitro (83). CD8 T cells producing TNFα and IFNγ may help to
amplify neutrophil functions, perhaps augmenting their oxidative mechanisms (80, 81) and/
or their production of inflammatory cytokines and chemokines (82). Exposure to TNFα and
IFNγ also can render macrophages non-permissive for intracellular Y. pestis replication
(84). Thus, T cells may combat plague by producing cytokines that help macrophages
restrict intracellular Y. pestis replication while enabling neutrophils to survive Y. pestis
encounters and kill extracellular bacteria in a fibrin(ogen)-dependent manner. Regardless of
the precise mechanism, the findings presented here demonstrate that one previously
unappreciated function of fibrin is to support neutrophil-dependent T cell-mediated defense
against bacteria.
This report also demonstrates that fibrin(ogen) is dispensable for immune defense against
plague mediated by optimal levels of protective Y. pestis-specific antibody even though it
contributes significantly to the partial protection conferred by suboptimal levels of antibody
(Figure 2). These observations are reminiscent of prior work demonstrating that TNFα and
IFNγ are dispensable for defense against plague mediated by optimal levels of antibody but
critical for defense mediated by suboptimal levels of antibody (40, 41). Given that T cells
also contribute to antibody-mediated defense against plague (85), these observations suggest
that T cells producing TNFα and IFNγ may provide fibrin-dependent defense that is
particularly critical when suboptimal levels of antibodies are present.
Further studies are required to establish why fibrin is dispensable for defense against plague
mediated by high levels of protective antibody. Prior studies indicate that antibodies to
either LcrV or F1 can interfere with the transport of effector proteins by the Y. pestis T3SS
(86-88). That observation suggests that fibrin may be dispensable for protection in the
presence of sufficient titers of antibody to effectively neutralize the T3SS, which functions
to intoxicate phagocytes. Consistent with that possibility, fibrin is not required when mice
are challenged with attenuated Y. pestis strain KIM D28 (data not shown), which lacks the
T3SS. However, another intriguing possibility is that optimal levels of antibody may bypass
requirements for fibrin-mediated enhancement of phagocyte survival by cross-linking
phagocyte Fc receptors, thereby providing phagocytes with fibrin(ogen)-independent
survival signals.
Studies over the past few decades have revealed remarkable interplay between
inflammation, immunity, and coagulation (25, 89-91). This report extends those connections
by demonstrating that coagulation leading to fibrin formation can critically influence both
innate and adaptive immunity. The accumulating evidence for essential protective roles for
fibrin during a variety of infections could help to explain why potent anticoagulant therapies
have failed to extend survival in septic patients (92, 93), and suggests that treatments for
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sepsis should strive to mitigate coagulopathy without preventing the formation of protective
fibrin.
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Figure 1. Fibrinogen contributes to innate defense against Y. pestis
(A) Survival of wild type C57BL/6 mice and RAG-deficient mice (RAG KO) after
intranasal challenge with 2×105 CFU Y. pestis strain KIM D27 (n=20-21 mice/group). (B)
Survival (n=18-19 mice/group) and (C) day 4 bacterial burden for fibrinogen-deficient mice
(Fib KO) and littermate control fibrinogen-heterozygous mice (Fib Het) after intranasal
challenge with 2×105 CFU KIM D27. (D) Survival (n=15-16 mice/group) and (E) day 4
bacterial burden for RAG/fibrinogen-deficient mice (RAG/Fib KO) and littermate control
RAG/fibrinogen-heterozygous mice (RAG/Fib Het) after intranasal challenge with 2×105
CFU KIM D27. (F) Survival of wild type C57BL/6 mice and RAG KO mice after intranasal
challenge with 2×106 CFU Y. pestis strain D27-pLpxL (n=15 mice/group). (G) Survival
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(n=18-20 mice/group) and (H) day 4 bacterial burden for Fib KO mice and littermate control
Fib Het mice after intranasal challenge with 2×106 CFU D27-pLpxL. (I) Survival (n=22-25
mice/group) and (J) day 4 bacterial burden for RAG/Fib KO mice and littermate control
RAG/Fib Het mice after intranasal challenge with 2×106 CFU D27-pLpxL. Data for all
panels is pooled from 2-3 independent experiments.
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Figure 2. Fibrinogen is dispensable for antibody-mediated defense against Y. pestis
(A,D,E,H) Survival (n=19-20 mice/group) and (B,C,F,G) day 4 bacterial burden for wild
type C57BL/6 mice, fibrinogen-deficient mice (Fib KO) and littermate control fibrinogen-
heterozygous mice (Fib Het) after intranasal challenge with 2×105 CFU Y. pestis strain KIM
D27 followed one day later by intraperitoneal treatment with (A-C) 10 ug LcrV-specific
mAb 7.3 (aLcrV), (E-G) 1 ug aLcrV, (D) 3 ug F1-specific mAb F1-04-A-G1 (aF1), or (H)
0.3 ug aF1. Control groups received isotype-matched control mouse IgG1 mAb. Data for all
panels is pooled from 2-3 independent experiments.
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Figure 3. Fibrinogen can be essential for T cell-mediated defense against Y. pestis
(A,D) Survival and (B,C,E,F) day 4 bacterial burden for wild type C57BL/6 mice,
fibrinogen-deficient mice (Fib KO) and littermate control fibrinogen-heterozygous mice (Fib
Het) after intranasal challenge with 2×105 CFU Y. pestis strain KIM D27. (A-C) The day
prior to infection, mice received intravenous injections of cell culture media (control) or
5×106 cultured polyclonal Y. pestis-primed T cells. (D-F) Prior to infection, mice were
immunized with YopE69-77 peptide or control ovalbumin peptide OVA257-264 (Ova). Data
for panels A-C and D-F are pooled from 2 and 4 independent experiments, respectively
(n=10 mice/group and 30-32 mice/group for A and D, respectively).
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Figure 4. Neutrophils contribute to T cell-mediated defense against Y. pestis
(A,B) Fibrinogen-deficient mice (Fib KO) and littermate control fibrinogen-heterozygous
mice (Fib Het) were immunized with YopE69-77 peptide or left unvaccinated (unvac
control). The YopE-immunized mice were challenged with 2×105 CFU Y. pestis strain KIM
D27 (D27) or left unchallenged (no D27). Four days after challenge, flow cytometry
revealed (A) similar numbers of lung CD8 T cells staining with KbYopE69-77 tetramer in Fib
Het and Fib KO mice and (B) significantly reduced numbers of lung neutrophils
(CD11b+Ly6G+) in the D27-challenged Fib KO mice. (C) Wild type C57BL/6 mice were
immunized with YopE69-77 peptide or received only cholera toxin adjuvant (CT), and then
all were challenged with 2×105 CFU Y. pestis strain KIM D27 (n=20 mice/group). As
indicated, mice received Ly6G-specific mAb 1A8 (aLy6G) or isotype-matched control rat
IgG2a mAb. Data for all panels is pooled from 2 independent experiments.
Luo et al. Page 23













Figure 5. Fibrinogen reduces hemorrhagic pathology and increases neutrophil viability during
immune defense against Y. pestis
Fibrinogen-heterozygous mice (Fib Het) and fibrinogen-deficient mice (Fib KO) were
challenged with (A,C,D,F,G,I,J,L) 2×105 CFU Y. pestis strain KIM D27 or (B,E,H,K)
2×106 CFU Y. pestis strain D27-pLpxL and hepatic tissue was collected four days after
initiating infections. Where indicated (C,F,I,L), mice were immunized with YopE69-77 prior
to challenge. (A-F) Representative paraformaldehyde-fixed samples stained with
hematoxylin and eosin stained sections (400x). Hemorrhagic pathology (collections of red
blood cells; black arrows) was evident in Fib KO mice challenged with D27-pLpxL (E) and
in the YopE-immunized Fib KO mice challenged with KIM D27 (F). (G-L) Representative
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fresh-frozen samples stained with anti-F1 to identify Y. pestis (green; white arrows), F4/80
to identify macrophages (blue), anti-Ly6G to identify neutrophils (red), and Hoescht dye to
identify nuclei (white). The white bar depicts 50 um. (M,N) Scoring of lesion types for mice
(n=5/group) described in A-F. The Material and Methods section describes the criteria used
for assigning lesion types. Typical type 1 lesions are shown in B and C; a typical lesions of
type 2 is shown in A; a typical type 3 lesion is shown in D; and typical type 4 lesions are
shown in E and F. The graphs depict (M) the number of lesions and (N) the percentage of
hemorrhagic lesions (type 3 and 4). Statistical significance was analyzed using Student's t-
tests.
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Figure 6. Fibrinogen-deficiency does not reduce infection-induced inflammation
Real-time PCR data showing levels of mRNA encoding TNFα, IFNγ, CXCL-1 and
lipocalin-2 in liver tissue collected four days after control or YopE-immunized mice were
challenged with 2×105 CFU Y. pestis strain KIM D27 or 2×106 CFU Y. pestis strain D27-
pLpxL. The data is presented as log10 fold-change relative to uninfected wild type mice
(n=13) and is pooled from 2-4 experiments (n=9-20 mice/group). Box and whisker plots
show the maximum, minimum, median, 25th percentile, and 75th percentile. The dotted line
depicts the mean value for uninfected wild type mice. Asterisks depict statistical
comparisons of each group to the uninfected wild type mice using Student's t-tests (*
p<0.01, ** p<0.001, *** p<0.0001). ns = not significant (p>0.05).
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Figure 7. Kinetics of fibrin formation during Y. pestis infection
Hepatic levels of (A) bacterial CFU, (B) fibrin, (C) TF mRNA, (D) FXI mRNA, (E) TAFI
mRNA, and (F) PAI-1 mRNA in wild type C57BL/6 mice at days 1-4 after intranasal
challenge with 2×105 CFU Y. pestis strain KIM D27 (solid symbols) or 2×106 CFU Y.
pestis strain D27-pLpxL (open symbols). Data shown is the median and interquartile range
for 14-15 mice per time point. The dashed line depicts the limit of detection (A,B) or the
average value for naïve control mice (C-F). Data for all panels is pooled from 2 independent
experiments. Asterisks depict statistical comparisons of D27 versus D27-pLpxL at day 4 (**
p<0.001, *** p<0.0001).
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Figure 8. Fibrin contributes to innate and T cell-mediated defense against Y. pestis
(A) Survival for FXI-deficient mice (FXI KO), control het-TF mice (mTF+/-hTF+), and low-
TF mice (mTF-/-hTF+) after intranasal challenge with 2×106 CFU Y. pestis strain D27-
pLpxL (p=0.008 for low-TF versus het-TF; n=9-10 mice/group). (B) Survival for YopE-
immunized FXI KO, het-TF and low-TF mice after intranasal challenge with 2×105 CFU Y.
pestis strain KIM D27 (p=0.003; for low-TF versus het-TF; n=6-8 mice/group). (C) Survival
for control C57BL/6 mice and coumadin-treated C57BL/6 mice after intranasal challenge
with 2×106 CFU Y. pestis strain D27-pLpxL (p=0.007; n=15 mice/group). (D) Survival for
YopE-immunized C57BL/6 mice and coumadin-treated YopE-immunized C57BL/6 mice
after intranasal challenge with 2×105 CFU Y. pestis strain KIM D27 (p=0.046; n=15 mice/
group). (E) Survival for wild type C57BL/6 mice and PAI-1/TAFI-deficient mice (P/T KO)
after intranasal challenge with 2×106 CFU Y. pestis strain D27-pLpxL (p=0.005; n=20-58
mice/group). (F) Survival for YopE-immunized wild type C57BL/6 mice and YopE-
immunized P/T KO mice after intranasal challenge with 2×105 CFU Y. pestis strain KIM
D27 (p=0.03; n=23-25 mice/group). Data for all panels is pooled from 2-4 independent
experiments.
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